Track topics on Twitter Track topics that are important to you
TORONTO, ONTARIO -- (Marketwired) -- 08/01/17 -- Maricann Group Inc. (CSE: MARI)(CSE: MARI.CN)(CNSX: MARI) ("Maricann" or the "Company") a low cost, greenhouse producer of medical cannabis with market leading technological, differentiation, is pleased to announce the appointment of Gerhard Muller as an independent member of the Company's Board of Directors, subject to regulatory approval.
Mr. Muller is a former audit partner of Ernst & Young's German practice, responsible partner for the Technology, Media & Entertainment sector at Ernst & Young for the Germany, Switzerland, Austria (GSA) region. A Certified Public Auditor and Tax consultant, Mr. Muller studied economics and English in Munich and Manchester (UK). At Ernst & Young, the majority of his clients were companies listed either in Europe or in the US. He left Ernst & Young in 2013 and has been working in his own practice since then. Since July 2017, Mr. Muller is also deputy chair of the Supervisory board of m4e AG, a German listed media company.
"We are pleased to welcome Gerhard to the Board of Directors of the Company. Gerhard's significant experience in international transactions, knowledge of reporting requirements, and business structuring will help to ensure the execution of our strategy and reliability of our reporting," stated Ben Ward, Chief Executive Officer of the Company.
About Maricann Group Inc.
Maricann is a vertically integrated producer and distributor of marijuana for medical purposes. The company was founded in 2013 and is based in Toronto with a facility in Langton, Ontario, where it operates a medicinal cannabis cultivation, extraction and distribution business under federal licence from the Government of Canada. Maricann, which has federal licences to cultivate, process and distribute cannabis, services a patient base with more than 8,000 total registered patients since inception. Maricann is currently undertaking an expansion of its cultivation and support facilities in Canada in a fully funded 217,000 sq. ft. (20,159 sq. m) build out, to support existing and future patient growth.
For more information about Maricann please visit our website at www.maricann.ca.
Forward Looking Information
Certain statements in this document contain forward-looking statements which can be identified by the use of forward-looking terminology such as "believes", "expects", "may", "desires", "will", "should", "projects", "estimates", "contemplates", "anticipates", "intends", or any negative such as "does not believe" or other variations thereof or comparable terminology. No assurance can be given that potential future results or circumstances described in the forward-looking statements will be achieved or will occur. By their nature, these forward-looking statements, necessarily involve risks and uncertainties, including those discussed herein, that could cause actual results to significantly differ from those contemplated by these forward-looking statements. Such statements reflect the view of the Company with respect to future events, and are based on information currently available to the Company and on assumptions, which it considers reasonable. Management cautions readers that the assumptions relative to the future events, several of which are beyond Management's control, could prove to be incorrect, given that they are subject to certain risk and uncertainties, and that actual results may differ materially from those projected. Factors which could cause results or events to differ from current expectations include, among other things: fluctuations in operating results; the impact of general economic, industry and market conditions; the ability to recruit and retain qualified employees; fluctuations in cash flow; increased levels of outstanding debt and obligations under a capital lease; expectations regarding market demand for particular products and the dependence on new product development; the impact of market change; and the impact of price and product competition. Management disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. The reader is cautioned not to place undue reliance on forward-looking information.Contacts: Investor Relations: Shawn Alexander VP Investor Relations 289-288-6284 Media: Carrie Booze North 6th Agency 212-334-9753 ext.142 Corporate Headquarters (Canada) Maricann Group Inc. (Toronto) 289-288-6274 European Headquarters (Germany) Maricann GmbH Thierschstrasse 3, 80538 Munchen, Deutschland NEXT ARTICLE
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...